EGFR signaling in breast cancer: Bad to the bone |
| |
| Authors: | John Foley Nicole K Nickerson Seungyoon Nam Kah Tan Allen Jennifer L Gilmore Kenneth P Nephew David J Riese II |
| |
| Institution: | a Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN 47405, United States;b Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, West Lafayette, IN 47907, United States;c Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN 46202, United States;d Indiana University Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, United States;e Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, United States |
| |
| Abstract: | The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases. This family includes EGFR/ErbB1/HER1, ErbB2/HER2/Neu ErbB3/HER3, and ErbB4/HER4. For many years it was believed that EGFR plays a minor role in the development and progression of breast malignancies. However, recent findings have led investigators to revisit these beliefs. Here we will review these findings and propose roles that EGFR may play in breast malignancies. In particular, we will discuss the potential roles that EGFR may play in triple-negative tumors, resistance to endocrine therapies, maintenance of stem-like tumor cells, and bone metastasis. Thus, we will propose the contexts in which EGFR may be a therapeutic target. |
| |
| Keywords: | Epidermal growth factor receptor Triple-negative tumors Resistance to endocrine therapy Stem-like tumor cells Bone metastasis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
